If You Invested in Legend Biotech Corporation (LEGN)
Looking for the current price? See the LEGN quote & overviewWhat $1,000 or $10,000 in LEGN Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jun 5, 2020 |
|---|---|---|---|---|
| $1,000 | $575 -42% | $291 -71% | — | $435 -56% |
| $10,000 | $5,750 -42% | $2,913 -71% | — | $4,351 -56% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-19. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for LEGN$1,000 Investment Over Time
LEGN vs S&P 500Year-by-Year Returns
LEGN annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2020Jun 5 to Dec 31 | $37.00 | $28.16 | -23.9% | -23.9% |
| 2021 | $28.16 | $46.61 | +65.5% | +26.0% |
| 2022 | $46.61 | $49.92 | +7.1% | +34.9% |
| 2023 | $49.92 | $60.17 | +20.5% | +62.6% |
| 2024 | $60.17 | $32.54 | -45.9% | -12.1% |
| 2025 | $32.54 | $21.74 | -33.2% | -41.2% |
| 2026Dec 31, 2025 to Nov 19 | $21.74 | $16.10 | -25.9% | -56.5% |
About Legend Biotech Corporation
Healthcare · NASDAQ
Legend Biotech Corporation (NASDAQ: LEGN) is a clinical and commercial stage biopharmaceutical company focused on cell therapy for oncology and other serious diseases. According to company disclosures, Legend Biotech is described as a global leader in cell therapy and the largest standalone cell therapy company, with thousands of employees and operations centered in the United States. The company’s work is rooted in the development of chimeric antigen receptor (CAR) T cell therapies, a form of personalized immunotherapy designed to treat cancers such as multiple myeloma and B‑cell non-Hodgkin lymphoma.
Core business and flagship therapy
Legend Biotech’s primary commercial focus is CARVYKTI® (ciltacabtagene autoleucel; cilta‑cel), a BCMA‑targeted CAR‑T cell therapy for relapsed or refractory multiple myeloma. The company states that CARVYKTI is a one‑time treatment that has been used in both clinical trials and commercial settings. CARVYKTI is developed and marketed under a collaboration and license agreement with Janssen (a Johnson & Johnson company), and collaboration revenue related to CARVYKTI is a major component of Legend Biotech’s reported revenues in its interim financial statements.
Company materials describe CARVYKTI as the market leader in multiple myeloma CAR‑T therapy and note that it is the first BCMA‑directed CAR‑T cell therapy approved for patients with multiple myeloma who have received at least one prior line of therapy. Legend Biotech reports that CARVYKTI has treated thousands of patients globally and is commercially available in multiple markets. Regulatory updates disclosed in SEC filings and press releases include U.S. Food and Drug Administration (FDA) and European Commission (EC) approvals of label updates to include overall survival benefit versus standard therapies, based on the Phase 3 CARTITUDE‑4 study.
Pipeline and cell therapy innovation
Beyond CARVYKTI, Legend Biotech reports a pipeline of cell therapy candidates. These include LUCAR‑G39D, an investigational anti‑CD20/CD19 dual‑CAR allogeneic gamma delta T cell therapy being evaluated in adults with relapsed or refractory B‑cell non‑Hodgkin lymphoma. Early Phase 1 data presented at the American Society of Hematology (ASH) Annual Meeting and summarized in company communications describe a manageable safety profile and encouraging antitumor activity.
The company also discloses additional autologous CAR‑T programs, such as LB2102, a DLL3‑targeted CAR‑T therapy in a Phase 1 trial for small‑cell lung cancer and large cell neuroendocrine carcinoma, and LB1908, a Claudin 18.2‑targeted CAR‑T product in a first‑in‑human study for advanced gastric, gastroesophageal, and esophageal adenocarcinoma. Legend Biotech further notes work on an in vivo platform technology, including a dual CD20/CD19‑targeted in vivo cell therapy candidate that has entered investigator‑initiated clinical evaluation.
Manufacturing and operational footprint
Legend Biotech emphasizes an “end‑to‑end” cell therapy model, encompassing research, development, manufacturing, and commercialization. Company reports highlight a major manufacturing presence, including a facility in Raritan, New Jersey that, after expansion, is described as the largest cell therapy manufacturing facility in the United States. This facility is intended to provide installed capacity to support treatment of up to 10,000 patients annually with CARVYKTI, subject to demand and regulatory considerations.
In addition, Legend Biotech has disclosed commercial production of CARVYKTI at a Tech Lane facility in Ghent, Belgium, following European Union approval, to support demand in Europe and other global markets. The company also reports opening a cell therapy research and development facility in Philadelphia, Pennsylvania, to support pipeline expansion across oncology and immunology and to advance in vivo approaches.
Collaborations and revenue model
Legend Biotech’s financial statements and SEC filings indicate that the company generates revenue primarily from license revenue and collaboration revenue. Collaboration revenue is largely tied to sales of CARVYKTI under the Janssen collaboration and license agreement, while license revenue includes amounts recognized under agreements such as the Novartis license for LB2102 and an exclusive agreement with a related party.
The company’s filings describe a component and product supply agreement under which Legend Biotech manufactures and supplies ciltacabtagene autoleucel to Janssen for clinical and commercial use outside Greater China, with costs and margins structured under the broader collaboration framework. Legend Biotech’s reported cash, time deposits, and collaboration funding arrangements are presented as providing financial resources to support ongoing operations and pipeline development.
Clinical programs and data disclosures
Legend Biotech regularly reports clinical data from its CARTITUDE program in multiple myeloma. Company communications describe results from CARTITUDE‑1 and CARTITUDE‑4, including long‑term progression‑free survival outcomes and analyses suggesting that earlier use of CARVYKTI is associated with stronger immune fitness and a more immunocompetent tumor microenvironment. The company also notes completion of enrollment in CARTITUDE‑6, a Phase 3 registrational trial in newly diagnosed, transplant‑eligible multiple myeloma patients, and initiation of CARTITUDE‑10, a Phase 2 multicohort trial in newly diagnosed patients.
In addition to efficacy data, Legend Biotech’s materials include extensive safety information for CARVYKTI, detailing risks such as cytokine release syndrome (CRS), immune effector cell‑associated neurotoxicity syndrome (ICANS), hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS), prolonged cytopenias, immune effector cell‑associated enterocolitis (IEC‑EC), and secondary hematologic malignancies. These safety disclosures reflect the approved product labeling and post‑marketing experience.
Regulatory and reporting status
Legend Biotech files as a foreign private issuer with the U.S. Securities and Exchange Commission, using Form 20‑F for annual reports and Form 6‑K for interim updates. The company is incorporated into multiple shelf registration statements on Form F‑3 and equity compensation registration statements on Form S‑8, as noted in its 6‑K filings. Recent 6‑Ks provide unaudited interim condensed consolidated financial statements, management’s discussion and analysis, and pipeline summaries for investors.
Available filings and news do not indicate any delisting, deregistration, or bankruptcy events. Legend Biotech’s ordinary shares continue to trade on the NASDAQ under the symbol LEGN, and its disclosures reference ongoing participation in investor conferences and healthcare industry meetings.
Position within pharmaceutical preparation manufacturing
Within the broader pharmaceutical preparation manufacturing sector, Legend Biotech focuses on cell‑based therapies rather than traditional small‑molecule drugs. Its activities include discovery and development of novel cell therapies for oncology and other indications, as described in earlier company profiles and confirmed by ongoing pipeline updates. The company’s emphasis on CAR‑T platforms, both autologous and allogeneic, and on in vivo cell therapy approaches, distinguishes its manufacturing and development requirements from those of conventional pharmaceutical producers.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Legend Biotech Corporation investment returns
How much would $1,000 invested in Legend Biotech Corporation be worth today?
If you invested $1,000 in Legend Biotech Corporation (LEGN) 5 years ago on 2021-11-19, your investment would be worth $291 as of 2026-11-19, a -70.9% price return without dividends, growing at a compounded rate of -21.9% per year (CAGR).
Has Legend Biotech Corporation outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare LEGN performance over available time periods.
What is Legend Biotech Corporation's average annual return?
The compound annual growth rate (CAGR) of LEGN’s share price over the past 5 years is -21.9%, without dividends. Individual years vary a great deal, and LEGN’s best recent full year was 2021 (+65.5%) while the worst was 2024 (-45.9%).
For informational and educational purposes only, not investment advice.